Related Experiment Video
Updated: Dec 4, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease
Kong-Xiang Zhu1,2, Pei-Yuan Song1,2, He-Li1,2
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.
Insights
The FMO3 rs1736557 AA genotype increases clopidogrel
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for coronary artery disease (CAD) patients post-percutaneous coronary intervention.
- High on-treatment platelet reactivity (HTPR) during clopidogrel therapy increases risks of stent thrombosis and ischemic events.
- CYP2C19 loss-of-function variants are known to cause HTPR; FMO3's role in platelet responsiveness is also noted.
Purpose of the Study:
- To investigate the association between the FMO3 rs1736557 polymorphism and clopidogrel response in Chinese CAD patients.
- To determine if FMO3 rs1736557 influences clopidogrel's antiplatelet potency.
Main Methods:
- 522 Chinese CAD patients receiving DAPT were studied.
- Platelet reactivity was measured using the vasodilator-stimulated phosphoprotein-phosphorylation assay after clopidogrel administration (loading or maintenance dose).
- FMO3 rs1736557 and CYP2C19 polymorphisms (*2, *3) were genotyped using PCR-RFLP.
Main Results:
- CYP2C19 poor and intermediate metabolizers exhibited significantly higher platelet reactivity than extensive metabolizers.
- FMO3 rs1736557 AA homozygotes showed significantly lower platelet reactivity compared to carriers of the G allele.
- The FMO3 rs1736557 A allele was associated with a significantly decreased risk of HTPR, particularly in patients with CYP2C19 loss-of-function alleles on maintenance dose therapy.
Conclusions:
- The FMO3 rs1736557 AA genotype is linked to enhanced antiplatelet potency of clopidogrel in Chinese CAD patients.
- This finding suggests FMO3 rs1736557 may be a genetic marker influencing clopidogrel efficacy.
- Further research is needed to validate these pharmacogenomic findings.
Purpose:
Dual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention to prevent stent thrombosis and ischemic events. However, some patients show high on-treatment platelet reactivity (HTPR) during clopidogrel therapy. Genetic factors such as loss-of-function variants of CYP2C19 are validated to increase the risk of HTPR. Flavin-containing monooxygenase 3 (FMO3) is reported to be associated with potency of platelet responsiveness and thrombosis. This study aimed to explore the association between FMO3 rs1736557 polymorphism and clopidogrel response.
Methods:
Five hundred twenty-two Chinese CAD patients treated with dual antiplatelet therapy were recruited from Xiangya Hospital. After oral administration of 300 mg loading dose (LD) clopidogrel for 12-24 h or 75 mg daily maintenance dose (MD) clopidogrel for at least 5 days, the platelet reaction index (PRI) was determined by vasodilator-stimulated phosphoprotein-phosphorylation assay. FMO3 rs1736557, CYP2C19*2, and CYP2C19*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results:
Mean PRI value was significantly higher in CYP2C19 poor metabolizers (PMs) and intermediate metabolizers (IMs) than the extensive metabolizers (EMs) (p < 0.001). In addition, FMO3 rs1736557 AA homozygotes showed significantly lower PRI as compared with carriers of the major rs1736557 G allele in the entire cohort and in the MD cohort (p = 0.011, p = 0.008, respectively). The risk of HTPR was decreased significantly in carriers of the rs1736557 A allele (AA vs GG: OR = 0.316, 95% CI: 0.137-0.726, p = 0.005; AA vs GA: OR = 0.249, 95% CI: 0.104-0.597, p = 0.001; AA vs GG+GA: OR = 0.294, 95% CI: 0.129-0.669, p = 0.002), and the association was observed mainly in patients carrying the CYP2C19 LOF allele and in those administered with MD.
Conclusion:
The FMO3 rs1736557 AA genotype was related to an increased the antiplatelet potency of clopidogrel in Chinese CAD patients. Additional studies are required to verify this finding.
More Related Videos
07:00A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Acute Coronary Syndrome III: Diagnostic Studies
Factors Affecting Drug Response: Overview
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease V: Interprofessional Care